For millions living with neurological and psychiatric conditions, medical innovation isn’t moving nearly fast enough. Today, global health systems are confronting a growing brain health crisis encompassing mental, neurological and cognitive well-being. With aging populations, mental health conditions affecting one in eight people worldwide, and the neurological consequences of chronic stress, novel solutions are needed urgently.
However, urgency alone doesn’t advance clinical development. In major markets like the U.S. and Europe, even a brilliant scientific discovery can spend years trapped in the bureaucratic pipeline between university laboratories and hospital trials, only to be delayed further by regulatory and payer hurdles.
Whenever we host global healthcare leaders in Israel, the first thing they notice isn’t just the entrepreneurial energy. It’s the intentional healthcare ecosystem. Supported by universal, HMO-based coverage, the country functions less like a fragmented market and more like a high-density national testbed for innovative output. It is a deliberate design that offers valuable lessons to the broader global market.
The Power of Proximity and Data
In Israel, the core assets are talent, geographical proximity, and integrated infrastructure. Because of the country’s tight geography, world-class research universities, major tertiary medical centers, and dozens of health-tech startups are often just a short drive or train ride away. World-renowned centers such as the Weizmann Institute of Science, Tel Aviv Medical Center and Technion – Israel Institute of Technology even share their campuses with accelerators, incubators, start-ups and VCs.
However, physical proximity is not enough without data, and lots of it. Israel backs this need with nearly 100% digitized, longitudinal electronic health records (EHR) spanning almost three decades. This data is consolidated across four major health plans and represents a diverse population from around the globe.
What does this translate to in practice? Speed and validation. A neuroscientist can walk across the street to validate a concept with a clinician over coffee, secure risk-mitigating early funding from the Israel Innovation Authority and test the concept against real-world health data, all while larger enterprises are still scheduling preliminary committee meetings that can take weeks or months to finalize.
With a population of just under 10 million, Israel isn’t meant to be the end market for breakthrough medical innovation. Instead, it serves as an agile proving ground, the ultimate real-world pressure test for clinically viable solutions before they scale globally.
Bridging the “Valley of Death” in Science
At FINN Partners, we work directly alongside these innovators as their ideas journey from lab to market, counseling global leaders seeking to tap into this supply chain of innovation.
One of the most important lessons we see? Science without an execution pathway wanders. However, purpose-built ecosystems create a fast track from idea to reality.
Look at Corundum Neuroscience, a venture builder created to translate early-stage neuroscience into market-ready digital therapeutics and medical devices. Driven by the reality that lab research is worthless if it never reaches a patient, Corundum acts as an engine turning raw science into scalable products.
Turning Local Need into Global “Traumatech”
The Israeli mindset is built on adapting under pressure, taking an immediate, acute problem and solving it smartly and fast.
We see this clearly in the rapid rise of “Traumatech” and neurotechnology. Driven by an acute localized need to treat trauma and PTSD, Israeli innovators have developed technologies with profound global applications.
We see this in practice with pioneering platforms like GrayMatters Health, which has developed an FDA-cleared digital therapeutic using advanced EEG-neurofeedback to help patients self-regulate the brain activity tied to trauma. Similarly, BrainsWay pioneered Deep Transcranial Magnetic Stimulation (Deep TMS) to non-invasively treat severe depression and OCD.
These technologies are already in the field. They are clinically validated, regulatory-reviewed, and scalable tools built under time pressure to treat pressing human suffering not in the distant future, but now.
This drive to take local breakthroughs and scale them globally is taking hold across brain health. Major gatherings like the Alzheimer’s Association International Conference (AAIC) and the AD/PD™ Conference highlight the vital work being done in Alzheimer’s, Parkinson’s, and related neurodegenerative conditions, elevating these solutions on the world stage.
The Bottom Line: Innovation Demands an Ecosystem
Tackling the global brain health crisis takes more than capital or exceptional science in isolation.
Success requires a working environment that dismantles silos among academia, clinical practice, government, and private capital. Israel didn’t build this incubator as an academic exercise. It built it through collaboration because it was essential to meet people’s health urgencies. The need was evident, the solution essential, and so the nation stripped away friction points that create unnecessary obstacles to validation and access.
For global pharma leaders, health systems, and investors, early partnership with a high-density innovation culture like Israel provides a high-speed engine for validating and de-risking brain health innovations.
Brain health cannot remain an isolated research priority or an afterthought within the broader health agenda. It demands a connected, cross-sector mission uniting science, technology, investment, policy and patient care. Israel has built an innovation infrastructure that offers a powerful model for global health.
Our goal now must be to build the communications bridges that connect these innovators and innovation hubs to global markets, ensuring brain health breakthroughs move smoothly through complex health systems into the hands of the patients whose lives they can change.
Ellie Hanson is a Senior Partner and Co-Lead of FINN Partners Israel. She specializes in cross-border communications, helping Israeli innovators scale effectively into global markets.
